Health in Tech, Inc. Announces Appointment of Christina R. Valauri as Independent Director and Member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee, Effective November 12, 2026


Health In Tech, Inc. announced the appointment of Christina R. Valauri to its Board of Directors as an independent director, effective November 12, 2026. Ms. Valauri will serve as a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Board. Ms. Valauri brings more than three decades of Wall Street and capital markets analytical, management and leadership experience, having held Managing Director and senior executive positions at prominent global financial institutions, including Cantor Fitzgerald, Natixis, ING Barings and Crédit Lyonnais.

Her leadership roles included Global Director of Equity Research at Cantor Fitzgerald and Co-Head of Equity Capital Markets at First Albany where she also served on the firm’s capital market operating committee. Throughout her career, she has led global research organizations, driven strategic business transformation and established regulatory and supervisory frameworks. A recognized healthcare investment research professional, Ms. Valauri was ranked No.

1 in the biomedical and biotechnology sector in The Wall Street Journal’s “Best on the Street” All-Star Analyst Survey. Throughout her career, Ms. Valauri has led international equity research teams across New York, London, Hong Kong and Toronto, built and managed institutional research organizations and implemented business transformation initiatives. She also brings substantial experience in corporate governance, regulatory oversight and risk management.

As a senior research executive and broker-dealer manager, she established regulatory and supervisory frameworks designed to uphold SEC and FINRA requirements and corporate governance best practices. Ms. Valauri spent more than 16 years as a senior sell-side equity research analyst covering pharmaceutical, biotechnology and medical technology companies in the U.S. and internationally, including at PaineWebber. Her analytical experience encompasses evaluating emerging healthcare technologies, assessing business models and competitive dynamics, and identifying commercial opportunities and investment considerations.

This research background, combined with her understanding of institutional investor expectations, provides valuable insight into the opportunities and challenges facing technology-driven healthcare companies. Ms. Valauri currently serves as an independent director of two other Nasdaq-listed companies, Valion Bio, Inc. since July 2024 and Precipio, Inc. since January 2024, bringing additional public company governance experience to our Board. She is also the Founder and CEO of Sagestone Advisory LLC, where she advises emerging companies on business strategy, capital markets positioning and growth initiatives.

Additionally, she serves as a Mentor and Guest Lecturer at Weill Cornell Medicine’s BioVenture eLab, where she previously served as Entrepreneur in Residence, supporting the development and commercialization of innovative healthcare technologies. Ms. Valauri holds an Executive MBA from Cornell University and a Bachelor of Arts in Biology from Reed College. She is also a National Association of Corporate Directors (NACD) Certified Director.

Leave a Reply

Your email address will not be published. Required fields are marked *